Related Experiment Videos
Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system
K S Webb1, S H Poulton, S N Liberman
1Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710.
Abstract:
A family of triple hybridomas secreting hybrid monoclonal antibodies has been developed in our laboratory. The hybrid monoclonal antibodies exhibit bimolecular specificity towards both antigenic determinants on the prostate carcinoma cell surface as well as toxin or toxic moieties (ricin A chain and pokeweed antiviral protein). These hybrid antibodies, when bound univalently to their cognate toxin, constitute the primary reagents responsible for selective in vitro prostate carcinoma cell kill; oncolytic impact is achieved by binding of the hybrid antibody-toxin complex (primary hybrid immunotoxin) to a prostate carcinoma cell surface-expressed antigen by the remaining univalent binding site of the hybrid antibody, allowing access of the toxin to the cytosol by internalization of the hybrid antibody-toxin complex. Internalization by endocytosis of a hybrid antibody-toxic subunit has been strikingly enhanced by the use of secondary monoclonal antibody reagents alone or in conjunction with other biomodifier reagents. For example, use of a second monoclonal antibody specific for ricin A chain to which ricin B chain (binding subunit) is chemically coupled results in selective and synergistic cell kill of targeted cancer cells. In vitro studies involving temporally staggered exposure of the cells to the individual components (primary hybrid antibody, toxin, and secondary antitoxin monoclonal antibody biomodifier) have been performed in a manner allowing maintenance of cytotoxic efficacy. It is concluded that sequential administration of these immunotherapeutic components, individually nontoxic, is a feasible strategy to develop an effective immunotherapeutic treatment of human prostate carcinoma.
Insights
Researchers developed hybrid monoclonal antibodies for targeted prostate cancer treatment. Sequential administration of these novel immunotherapeutic agents shows promise for effective in vitro cancer cell kill.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Prostate carcinoma presents a significant challenge in cancer therapy.
- Targeted drug delivery systems are crucial for improving treatment efficacy and reducing side effects.
Purpose of the Study:
- To develop and evaluate a novel immunotherapeutic strategy for prostate carcinoma.
- To assess the efficacy of hybrid monoclonal antibodies conjugated with toxins for selective cancer cell killing.
Main Methods:
- Development of triple hybridomas secreting hybrid monoclonal antibodies with dual specificity.
- Conjugation of hybrid antibodies to cytotoxic agents (ricin A chain, pokeweed antiviral protein).
- In vitro evaluation of hybrid antibody-toxin complexes for selective cancer cell lysis, including enhancement with secondary antibodies.
Main Results:
- Hybrid monoclonal antibodies demonstrated specific binding to prostate carcinoma cells and toxins.
- The hybrid antibody-toxin complexes effectively killed prostate carcinoma cells in vitro.
- Sequential administration of non-toxic components resulted in synergistic and selective cancer cell kill.
Conclusions:
- Sequential administration of individually non-toxic immunotherapeutic components is a feasible strategy.
- This approach offers a potential pathway for developing effective immunotherapies for human prostate carcinoma.